SCHEMBL19951273

SCHEMBL19951273

CNC(=O)c1cccc(C(C)n2nc(C)c(NC(=O)c3ccc(COc4ccccc4)cc3)c2C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
MRGPRX4 Q96LA9 1/20 0.46
POLB P06746 1/20 0.46
RXFP1 Q9HBX9 1/20 0.45
ALDH1A1 P00352 4/20 0.45
LMNA P02545 2/20 0.45
SMN1; SMN2 Q16637 4/20 0.44
TSHR P16473 1/20 0.44
NR1H4 Q96RI1 3/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
HTT P42858 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43
MAPT P10636 2/20 0.43
CTDSP1 Q9GZU7 1/20 0.42
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19951269 0.85 MRGPRX4 (0.51) MEN1KMT2ANPC1RAB9AMRGPRX4
SCHEMBL19951326 0.81 SMN1; SMN2 (0.61) MEN1KMT2ANPC1RAB9AMRGPRX4
SCHEMBL19951344 0.79 SMN1; SMN2 (0.60) MEN1KMT2ANPC1RAB9ARXFP1
SCHEMBL19951245 0.79 SMN1; SMN2 (0.64) MEN1KMT2ANPC1RAB9AMRGPRX4
SCHEMBL19951200 0.77 SMN1; SMN2 (0.60) MEN1KMT2ANPC1RAB9ARXFP1
SCHEMBL19951225 0.77 SMN1; SMN2 (0.66) MEN1KMT2ANPC1RAB9AMRGPRX4
SCHEMBL19951197 0.76 SMN1; SMN2 (0.62) MEN1KMT2ANPC1RAB9AMRGPRX4
SCHEMBL19951258 0.75 SMN1; SMN2 (0.61) MEN1KMT2ANPC1RAB9AMRGPRX4
SCHEMBL19951281 0.75 SMN1; SMN2 (0.59) MEN1KMT2ANPC1RAB9AMRGPRX4
SCHEMBL19951304 0.75 SMN1; SMN2 (0.57) MEN1KMT2ANPC1RAB9AMRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10357477-B2 Anticancer compounds REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2019-07-23 US disclosed
US-10357477-B2 Anticancer compounds REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2019-07-23 US disclosed
US-20180071258-A1 ANTICANCER COMPOUNDS REGENTS OF THE UNIVERSITY OF MINNESOTA 2018-03-15 US disclosed
US-20180071258-A1 ANTICANCER COMPOUNDS REGENTS OF THE UNIVERSITY OF MINNESOTA 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180071258-A1 ANTICANCER COMPOUNDS RB1, MCL1, TP53 MEN1 603/4885KMT2A 2137/4885NPC1 890/4885
US-10357477-B2 Anticancer compounds RB1, MCL1, TP53 MEN1 603/4885KMT2A 2137/4885NPC1 890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.